Azathioprine induced serious portal hypertension: A case series of three IBD patients and review of the literature

Acta Gastro-Enterologica Belgica

Volumn 76, Issue 3, 2013, Pages 342-346

  Dooremont, D ^a,b   Decaestecker, J ^a   de Wulf, D ^a   Ghillebert, G ^a   van Vlierberghe, H ^b   van Dorpe, J ^a   Baert, F ^a  

^a Heilig Hart Ziekenhuis   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Azathioprine; Case series; IBD; Nodular regenerative hyperplasia; Portal hypertension

Indexed keywords

ADULT; AZATHIOPRINE; HUMANS; HYPERTENSION, PORTAL; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; PORTAL PRESSURE;

EID: 84887010454     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. CALNE R. Essay: History of transplantation. The Lancet, 2006, 368 (Suppl 1): S51-S52.
2. HARTLEB M., GUTKOWSKI K., MILKIEWICZ P. Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension. World. J. Gastroenterol., 2011, 17 (11): 1400-1409.
3. CATURELLI E., GHITTONI G., RANALLI T.V., GOMES V.V. Nodular regenerative hyperplasia of the liver: coral atoll-like lesions on ultrasound are characteristic in predisposed patients. Brit. J. Radiol., 2011, 84: e129- e134.
4. GEARRY R.B., DAY A.S., BARCLAY M.L., LEONG R.W.L, SPARROW M.P. Azathioprine and allopurinol: A two-edged interaction. J. Gastroenterology. Hepatol., 2010, 25: 653-655.
5. http://www.uptodate.com/contents/6-mercaptopurine-6-mp-metabolite- monitoring-and-TPMT-testing-in-the-treatment-of-inflammatory-boweldiseas e-with-6-mp-or-azathioprine
6. SPARROW M.P., HANDE S.A., FRIEDMAN S., CAO D., HANAUER S.B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease non- responders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepa- tol., 2007, 5 (2): 209-214.
7. SPARROW M.P., HANDE S.A., FRIEDMAN S. et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel dis- ease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther., 2005, 22: 441-446.
8. DUBINSKY M.C., VASILIAUSKAS E.A., SINGH H. et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastro-lenterology, 2003, 125: 298-303.
9. Vernier-Massouille G., COSNES J., LEMANN M. et al. Nodular re- generative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut, 2007, 56: 1404-1409.
10. SEKSIK P., MARY J-Y., BEAUGERIE L. et al. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm. Bowel. Dis., 2011, 17: 565-572.
11. ARVANITAKI M., ADLER M. Nodular regenerative hyperplasia of the liver. A review of 14 cases. Hepatogastrol., 2001, 48 (41): 1425-1429.
12. SEIDERER J., ZECH C.J., DIEBOLD J. et al. Nodular regenerative hyper- plasia: a reversible entity associated with azathioprine therapy. Eur. J. Gastroenterol. Hepatol., 2006, 18: 553-555.
13. LAHARIE D., VERGNIOL J., BIOULAC-SAGE P. et al. Usefulness of non- invasive tests in nodular regenerative hyperplasia of the liver. Eur. J. Gastroenterol. Hepatol., 2010, 22: 487-493.
14. IBAROLLA C., COLINA F. Clinicopathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inade- quate. Histopathology, 2003, 42: 251-264
15. NZEAKO U.C., GOODMAN Z.D., ISHAK K.G. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship. Am. J. Gastroenterol., 1996 May, 91 (5): 879-884.